APIs and pharmaceutical intermediates have changed in individual stocks, and many pharmaceutical companies have achieved a limit increase today

In recent years, China has issued a series of policies to support the rapid development of the pharmaceutical manufacturing industry and encourage the development and innovation
of the pharmaceutical manufacturing industry.
The formulation of relevant industrial policies provides a clear and broad market prospect for the development of pharmaceutical manufacturing and APIs and pharmaceutical intermediates industries, and provides a good production and operation environment
for enterprises.
Data predict that in 2022, the market size of China's pharmaceutical intermediates will reach 227.
8 billion yuan, and the output will reach 10.
29 million tons
.
On January 9, the individual stocks of pharmaceutical intermediates changed, and Huasoft Technology touched the limit of increase, and the stock rose 5 times
in the past year.
Data show that at 10:56 on January 9, Huasoft Technology rose to 11.
63 yuan intraday, and the current order is 217200 lots, equivalent to 253 million yuan
.
Up to now, the transaction has reached 125 million yuan, with a turnover rate of 1.
78%.

According to the data, the main business of Huasoft Technology is the research and development, production and sales of fine chemical products, as well as supply chain management business
.
The company's main products are papermaking chemicals, pharmaceutical pesticide intermediates, fluorescent brighteners, electronic chemicals, ICT product supply, mobile solution consulting, implementation and operation and maintenance management, technical training, mobile equipment life cycle services, operating leasing services
.
The main products of the company's pharmaceutical intermediates are intermediates
for the treatment of depression, diabetes, cardiovascular diseases and cough.
It is reported that in the field of pharmaceutical intermediates, after years of development, Huasoft Technology has maintained cooperation with a number of enterprises, including API manufacturing companies Takeda Pharmaceutical, Tanabe Pharmaceutical, France MINAKEM, the United States AMRI, Taiwan Taiyao Chemical, India's large generic drug company Cadila, Kailaiying, etc.
, and many of its products have strong market competitiveness and stable market demand
。 As a pharmaceutical intermediate manufacturer with the ability to synthesize caronic anhydride and nitrogen bicyclic whole industrial chain, Huasoft Technology has made progress in the synthesis process route of two intermediates SM1 and SM2 of parovide intermediate, and is optimizing the process route
.
In addition to Huasoft Technology, East Asia Pharmaceutical also touched the limit board today, and the stock has risen 3 times
in the past year.
Data show that at 11:19 on January 9, East Asia Pharmaceutical opened an intraday limit of 22.
98 yuan, with a transaction of 103 million yuan and a turnover rate of 8.
09%.

The stock previously traded at 10:33 a.
m
.
According to the data, the main business of East Asia Pharmaceutical is engaged in the research and development, production and sales
of chemical APIs and pharmaceutical intermediates.
At present, the products of East Asia Pharmaceutical mainly involve antibacterial drugs, anticholinergic and synthetic antispasmodic drugs, antifungal drugs for the skin, and other products, and its products mainly cover antibacterial drugs (β-lactams and quinolones), anticholinergic and synthetic antispasmodic drugs (trimebutine maleate), antifungal drugs for the skin and other pharmaceutical fields
.
Among them, East Asia Pharmaceutical has core independent products
in many fields such as anti-pathogenic microbial infection, diabetic neuropathy, anti-senile dementia, cardiovascular and cerebrovascular, central nervous system, digestive system and so on.
Data show that in the first half of 2022, the revenue of East Asia Pharmaceutical was 535 million yuan, a year-on-year increase of 55.
14%.

The strong R&D strength and quality reputation of East Asia Pharmaceutical have brought strong impetus
to the take-off of enterprises.
It is reported that East Asia Pharmaceutical has a modern R&D center and a scientific research team
mainly based on doctors and masters in Shanghai International Medical Park.
The company sits on the location of the national chemical API production base in Taizhou, Zhejiang, and can fully enjoy the dividends of the industrial cluster and quickly promote the implementation of the project
.
In addition, the company's core products have generally obtained CGMP, European Union (EDQM), Japan Ministry of Health and Welfare (PMDA) certification
, etc.
Analysts pointed out that in recent years, China has continuously increased the empowerment of the API and intermediate industries from the policy level, such as the "14th Five-Year Plan" pharmaceutical industry development plan, "14th Five-Year Plan" national pesticide industry development plan, "Implementation Plan for promoting the high-quality development of the API industry", etc.
, a series of favorable policies have been released, comprehensively promoting the industrial structure adjustment and optimization and upgrading
of the industry.
The national policy clearly proposes to support and regulate enterprises, eliminate backward production capacity, increase industrial concentration, and improve the competitive environment
.
In the process of standardized and orderly development of the industry, the core competitiveness of enterprises represented by East Asia Pharmaceutical will be further reflected, and high-quality development will also become the main theme
of the industry.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.